Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
D'Ambrosio L, Touati N, Blay JY, Grignani G, Flippot R, Czarnecka AM, Piperno-Neumann S, Martin-Broto J, Sanfilippo R, Katz D, Duffaud F, Vincenzi B, Stark DP, Mazzeo F, Tuchscherer A, Chevreau C, Sherriff J, Estival A, Litière S, Sents W, Ray-Coquard I, Tolomeo F, Le Cesne A, Rutkowski P, Stacchiotti S, Kasper B, Gelderblom H, Gronchi A; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. D'Ambrosio L, et al. Among authors: estival a. Cancer. 2020 Jun 1;126(11):2637-2647. doi: 10.1002/cncr.32795. Epub 2020 Mar 4. Cancer. 2020. PMID: 32129883 Free article.
Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG "ANITA".
Schöffski P, Toulmonde M, Estival A, Marquina G, Dudzisz-Śledź M, Brahmi M, Steeghs N, Karavasilis V, de Haan J, Wozniak A, Cousin S, Domènech M, Bovée JVMG, Charon-Barra C, Marreaud S, Litière S, De Meulemeester L, Olungu C, Gelderblom H. Schöffski P, et al. Among authors: estival a. Eur J Cancer. 2021 Jul;152:26-40. doi: 10.1016/j.ejca.2021.04.015. Epub 2021 May 29. Eur J Cancer. 2021. PMID: 34062484 Free article. Clinical Trial.
SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016).
Poveda A, Martinez V, Serrano C, Sevilla I, Lecumberri MJ, de Beveridge RD, Estival A, Vicente D, Rubió J, Martin-Broto J. Poveda A, et al. Among authors: estival a. Clin Transl Oncol. 2016 Dec;18(12):1221-1228. doi: 10.1007/s12094-016-1579-9. Epub 2016 Nov 28. Clin Transl Oncol. 2016. PMID: 27896638 Free PMC article.
Pseudoprogression as an adverse event of glioblastoma therapy.
Balaña C, Capellades J, Pineda E, Estival A, Puig J, Domenech S, Verger E, Pujol T, Martinez-García M, Oleaga L, Velarde J, Mesia C, Fuentes R, Marruecos J, Del Barco S, Villà S, Carrato C, Gallego O, Gil-Gil M, Craven-Bartle J, Alameda F; GLIOCAT Group. Balaña C, et al. Among authors: estival a. Cancer Med. 2017 Dec;6(12):2858-2866. doi: 10.1002/cam4.1242. Epub 2017 Nov 3. Cancer Med. 2017. PMID: 29105360 Free PMC article.
Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients.
Balaña C, Estival A, Teruel I, Hardy-Werbin M, Sepulveda J, Pineda E, Martinez-García M, Gallego O, Luque R, Gil-Gil M, Mesia C, Del Barco S, Herrero A, Berrocal A, Perez-Segura P, De Las Penas R, Marruecos J, Fuentes R, Reynes G, Velarde JM, Cardona A, Verger E, Panciroli C, Villà S. Balaña C, et al. Among authors: estival a. Clin Transl Oncol. 2018 Dec;20(12):1529-1537. doi: 10.1007/s12094-018-1883-7. Epub 2018 May 8. Clin Transl Oncol. 2018. PMID: 29737461
A Timely Oral Option: Single-Agent Vinorelbine in Desmoid Tumors.
Gennatas S, Chamberlain F, Smrke A, Stewart J, Hayes A, Roden L, Messiou C, Kowa JY, Estival A, Chauhan D, Thway K, Fisher C, van der Graaf WTA, Jones RL, Benson C. Gennatas S, et al. Among authors: estival a. Oncologist. 2020 Dec;25(12):e2013-e2016. doi: 10.1002/ONCO.13516. Epub 2020 Oct 2. Oncologist. 2020. PMID: 32918789 Free PMC article.
Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study.
Ruano-Ravina A, Provencio M, Calvo de Juan V, Carcereny E, Estival A, Rodríguez-Abreu D, Benítez G, López-Castro R, Belver M, Guirado-Risueño M, Guirao-Rubio C, Blasco A, Massutí B, Ortega AL, Cobo M, Mosquera-Martínez J, Aguado de la Rosa C, Bosch-Barrera J, Sánchez-Gastaldo A, Del Barco Morillo E, Juan Ó, Dómine M, Trigo JM, Pereiro Corbacho D, Oramas J. Ruano-Ravina A, et al. Among authors: estival a. Transl Lung Cancer Res. 2021 Oct;10(10):3902-3911. doi: 10.21037/tlcr-21-559. Transl Lung Cancer Res. 2021. PMID: 34858780 Free PMC article.
Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.
Kim DW, Chul Cho B, Pachipala K, Kim SW, Wang CL, Chang GC, Ahn MJ, Alvarez R, Chiu CH, Trigo J, Estival A, Karam SD, O'Brien C, Gowda H, Jiang H, Bauman JE. Kim DW, et al. Among authors: estival a. Lung Cancer. 2024 Apr;190:107530. doi: 10.1016/j.lungcan.2024.107530. Epub 2024 Mar 7. Lung Cancer. 2024. PMID: 38471416 Free article. Clinical Trial.
Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumab.
Panciroli C, Lucente G, Vidal L, Carcereny E, Quiroga V, Pardo JC, Romeo M, Estival A, Manzano JL, Pardo B, Velarde JM, Esteve AM, Lopez D, Mañes A, Tuset V, Villà S, Quintero CB. Panciroli C, et al. Among authors: estival a. Clin Transl Oncol. 2020 Mar;22(3):411-419. doi: 10.1007/s12094-019-02143-6. Epub 2019 May 29. Clin Transl Oncol. 2020. PMID: 31144211
62 results